Thermo Fisher Scientific acquires transplant diagnostic company

Skip to Navigation


Thermo Fisher Scientific has agreed to acquire One Lambda, a US developer of transplant diagnostics, for US$925 million. With sales of US$182 million in 2011 and 320 employees, One Lambda will now become part of Thermo Fisher's specialty diagnostics business segment.

'With its strong technology platform, high margin profile and good growth prospects, the business is perfectly aligned with our specialty in vitro diagnostics strategy,' says Marc Casper, president and chief executive officer of Thermo Fisher. 'One Lambda gives us access to the attractive transplant diagnostics market and complements our existing immunosuppressant monitoring assays.'

Founded in 1984 as a spin out from the University of California, Los Angeles, One Lambda has developed a variety of serological, antibody and genetic tests for determining the compatibility of organs for transplant into patients, and for detecting the presence of antibodies that can lead to transplant rejection.

'We are excited about the opportunities ahead as we join Thermo Fisher’s specialty diagnostics business,' says George Ayoub, co-founder, president and chief executive officer of One Lambda. 'I believe that, together, we will increase the use of human leukocyte antigen (HLA) typing and antibody detection to accelerate growth and improve the success rate of transplantation.'

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved